IMPROVE-IT Trial: Statin Plus Ezetimibe in Acute Coronary Syndrome
Overview of IMPROVE-IT
- The American Heart Association recommends adding ezetimibe to statin therapy for patients with acute coronary syndrome, as it reduces cardiovascular events in high-risk patients 1, 2, 3
Trial Design and Population
- The IMPROVE-IT trial enrolled 18,144 patients aged ≥50 years who had experienced a recent acute coronary syndrome, and were stabilized within 10 days of the event, with a median follow-up of 6-7 years 1, 2, 4
- Patients had moderately elevated LDL cholesterol levels at baseline, and were treated with simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg monotherapy 2, 4
Primary Results and LDL-C Reduction
- The combination therapy achieved an average LDL-C of 54 mg/dL, compared to 70 mg/dL with simvastatin monotherapy, resulting in an additional 24% reduction in LDL-C 1, 4
- The primary composite endpoint was reduced by 6.4% relative risk, translating to a 2% absolute risk reduction in major adverse cardiovascular events over 7 years 1, 2, 3
Critical Subgroup Analyses
- Among patients with diabetes, combination therapy showed a 5% absolute risk reduction and 14% relative risk reduction in major adverse cardiovascular events 2, 3, 4
- The European Society of Cardiology endorses ezetimibe as the preferred first-line nonstatin agent due to its proven cardiovascular benefit and lower cost compared to PCSK9 inhibitors 5, 6
Clinical Implications and Guideline Integration
- The American Heart Association and American Diabetes Association recommend adding ezetimibe 10 mg to maximum tolerated statin therapy when LDL-C goals are not achieved 1, 3
- For patients with recent acute coronary syndrome, simultaneous initiation of statin plus ezetimibe may be considered to achieve rapid LDL-C reduction and early risk reduction 7